Clinical trial of Sinudrain HaftBahr solution

Evaluation of therapeutic potential of Sinudrain HaftBahr solution in the treatment process of Covid 19 disease (clinical trial)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210914052471N1

Enrollment

Registered

2021-10-01

Start date

2021-10-12

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid 19. Covid-19, virus identified

Interventions

Intervention 1: Intervention group: In this group, the treatment regimen is in the form of routine protocol (RamedSavier two injectable doses for 5 days) + the drug Synodrine Haft Bahr. Iranian medica

Eligibility

Sex/Gender

All

Age

17 Years to 70 Years

Inclusion criteria

Inclusion criteria: Individuals with positive PCR test Covid19 Blood oxygen levels above 80 Age between 17 and 65 years Pulmonary involvement less than 40% Patients who do not need to use a ventilator

Exclusion criteria

Exclusion criteria: History of uncontrolled hypertension

Design outcomes

Primary

Measure	Time frame
SPO2. Timepoint: Daily. Method of measurement: Using a pulse oximeter.;Feeling of tightness in the throat. Timepoint: Daily. Method of measurement: Patient history.	—

Secondary

Measure	Time frame
Duration of patient treatment time. Timepoint: End of clinical symptoms. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamid Chegni

Shahid Beheshti University of Medical Sciences

h.chegini2010@yahoo.com+98 21 2258 4586

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026